SCHEMBL5362776

SCHEMBL5362776

COc1c(Br)cc(C=C2C(=O)Nc3ccc(Br)c(C)c32)cc1C(C)(C)C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.67
EGFR P00533 4/20 0.67
PLK4 O00444 2/20 0.50
LRRK2 Q5S007 3/20 0.44
IGF1R P08069 2/20 0.42
RAF1 P04049 5/20 0.40
AURKA O14965 1/20 0.40
TTR P02766 1/20 0.40
INSR P06213 1/20 0.40
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAP1LC3B Q9GZQ8 2/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5366011 0.96 ERBB2 (0.61) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5376941 0.91 ERBB2 (0.61) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5357756 0.91 ERBB2 (0.56) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5367544 0.87 ERBB2 (0.52) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5366009 0.85 ERBB2 (0.62) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5360968 0.85 EGFR (0.54) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5363012 0.85 ERBB2 (0.56) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5364049 0.84 ERBB2 (0.59) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL7132027 0.84 ERBB2 (0.60) ERBB2EGFRPLK4LRRK2IGF1R
SCHEMBL5358747 0.83 PLK4 (0.60) ERBB2EGFRPLK4LRRK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885PLK4 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.